Skip to content
2000
Volume 29, Issue 23
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background: The current coronavirus disease 2019 (COVID-19) pandemic, since first reported in Wuhan, has inspired worldwide efforts to develop effective COVID-19 vaccination strategies. mRNA vaccines encoding COVID-19 antigens have emerged prominantlyin this global race due to their high effectiveness and simple manufacturing process. Notably, two COVID-19 mRNA vaccines, mRNA-1273 and BNT162b2, have survived in clinical trials and been authorized for emergency use across variouscountries. Summary: Recent advances on mRNA vaccine development for COVID-19 are discussed in this perspective, including sequence design, chemical modification, manufacturing process, and in vivo delivery. Phase I to IV clinical trials of mRNA-1273 and BNT162b2 are then summarized, respectively. Conclusion: Using mRNA vaccines is a promising strategy to achieve mass vaccination in the COVID-19 pandemic. We hope that future studies of mRNA vaccine technology will overcome existing limitations and help people cope with COVID-19.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867329666220216110931
2022-07-01
2025-07-03
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867329666220216110931
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test